Stephan Stilgenbauer
Stephan Stilgenbauer is an expert in Hematology at University Hospital Ulm (Germany). As of October 2026, ScienceLeadR ranks Stephan Stilgenbauer in the top 1% of experts worldwide for Leukemia, Lymphoproliferative Disorders and Lymphoma. Stephan Stilgenbauer has authored 1,036 publications, the most recent in 2026, and is an investigator in 54 clinical trials, 4 of them ongoing. SLR score: 4,252 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Oncology - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1993 - 2026
Number : 1036
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Comment on "EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation". PMID 42871435 — leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid | Hemasphere | 2026 | 0 |
| Telomere length in chronic lymphocytic leukemia treated with venetoclax-based regimen in GAIA/CLL13 and CLL2-GIVe trials. PMID 42837320 — hematology, leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid, lymph, therapeutics, telomere | Blood | 2026 | 0 |
| Erratum to: "Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia". PMID 42817752 — precursor cell lymphoblastic leukemia-lymphoma, hematology, leukemia, therapeutics | Haematologica | 2026 | 0 |
| Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy. PMID 42659576 — leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid, therapeutics | J Clin Oncol Top journal | 2026 | 0 |
| High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial. PMID 42486133 — cells, embolism, safety, microscopy, electron, scanning transmission, progression-free survival, lymphoma, stem cells, drug therapy, drug-related side effects and adverse reactions, rituximab, pulmonary embolism, therapeutics, cell transplantation, stem cell transplantation, transplantation, universities, infections, thiotepa, chemotherapy | Lancet Top journal | 2026 | 4 |
Clinical Studies 54
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 4
Ongoing Clinical Trials
4 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Venetoclax in combination with Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients with Mantle Cell Lymphoma 2022-501808-96-00 — cells, lymphoma, drug therapy, rituximab, lymphoma, mantle-cell, therapeutics, chemotherapy | Phase 2 | Recruiting | 2023 |
| A Phase 3 Study Comparing Pirtobrutinib to Ibrutinib in CLL SLL 2023-507699-38-00 — lymphoma, leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid | Phase 3 | Active not recruiting | 2022 |
| Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment na ve or Relapsed Refractory CLL NCT04883749 — cells, leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid, therapeutics, b-lymphocytes | Phase 2 | Active not recruiting | 2021 |
| Ibrutinib Monotherapy Versus Fixed duration Venetoclax Plus Obinutuzumab Versus Fixed duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) NCT04608318 — cells, leukemia, leukemia, lymphoid, b-lymphocytes, leukemia, b-cell | Phase 3 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map